Morgan Stanley’s OncoSec Medical Incorporated ONCS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-73
| Closed | -$188 | – | 7847 |
|
|
2023
Q1 | $188 | Hold |
73
| – | – | ﹤0.01% | 7520 |
|
|
2022
Q4 | $123 | Buy |
73
+2
| +3% | +$11 | ﹤0.01% | 7682 |
|
|
2022
Q3 | $1K | Hold |
71
| – | – | ﹤0.01% | 7668 |
|
|
2022
Q2 | $1K | Hold |
71
| – | – | ﹤0.01% | 7763 |
|
|
2022
Q1 | $2K | Hold |
71
| – | – | ﹤0.01% | 7814 |
|
|
2021
Q4 | $2K | Sell |
71
-5
| -7% | -$169 | ﹤0.01% | 7838 |
|
|
2021
Q3 | $4K | Sell |
76
-164
| -68% | -$8.31K | ﹤0.01% | 7584 |
|
|
2021
Q2 | $15K | Buy |
240
+5
| +2% | +$454 | ﹤0.01% | 7118 |
|
|
2021
Q1 | $25K | Buy |
235
+37
| +19% | +$5.06K | ﹤0.01% | 6658 |
|
|
2020
Q4 | $28K | Buy |
198
+135
| +214% | +$14.4K | ﹤0.01% | 6350 |
|
|
2020
Q3 | $5K | Buy |
63
+58
| +1,160% | +$4.52K | ﹤0.01% | 6463 |
|
|
2020
Q2 | $0 | Hold |
5
| – | – | ﹤0.01% | 6912 |
|
|
2020
Q1 | $0 | Sell |
5
-16
| -76% | -$597 | ﹤0.01% | 6935 |
|
|
2019
Q4 | $1K | Sell |
21
-62
| -75% | -$2.8K | ﹤0.01% | 6625 |
|
|
2019
Q3 | $4K | Sell |
83
-7
| -8% | -$329 | ﹤0.01% | 6420 |
|
|
2019
Q2 | $5K | Buy |
90
+7
| +8% | +$674 | ﹤0.01% | 6336 |
|
|
2019
Q1 | $10K | Sell |
83
-36
| -30% | -$4.92K | ﹤0.01% | 6198 |
|
|
2018
Q4 | $17K | Buy |
119
+90
| +310% | +$22.6K | ﹤0.01% | 6054 |
|
|
2018
Q3 | $9K | Buy |
29
+19
| +190% | +$5.84K | ﹤0.01% | 6340 |
|
|
2018
Q2 | $3K | Hold |
10
| – | – | ﹤0.01% | 6526 |
|
|
2018
Q1 | $4K | Buy |
10
+3
| +43% | +$1.23K | ﹤0.01% | 6439 |
|
|
2017
Q4 | $2K | Buy |
7
+3
| +75% | +$1.05K | ﹤0.01% | 6461 |
|
|
2017
Q3 | $0 | Sell |
4
-3
| -43% | -$669 | ﹤0.01% | 6680 |
|
|
2017
Q2 | $2K | Buy |
7
+5
| +250% | +$1.23K | ﹤0.01% | 6478 |
|
|
2017
Q1 | $1K | Sell |
2
-26
| -93% | -$7.57K | ﹤0.01% | 6535 |
|
|
2016
Q4 | $8K | Buy |
28
+17
| +155% | +$5.84K | ﹤0.01% | 6212 |
|
|
2016
Q3 | $4K | Sell |
11
-2
| -15% | -$766 | ﹤0.01% | 6291 |
|
|
2016
Q2 | $5K | Buy |
13
+2
| +18% | +$842 | ﹤0.01% | 6235 |
|
|
2016
Q1 | $6K | Hold |
11
| – | – | ﹤0.01% | 6258 |
|
|
2015
Q4 | $6K | Sell |
11
-1
| -8% | -$752 | ﹤0.01% | 6353 |
|
|
2015
Q3 | $14K | Sell |
12
-195
| -94% | -$256K | ﹤0.01% | 6169 |
|
|
2015
Q2 | $288K | Buy |
+207
| New | +$310K | ﹤0.01% | 5059 |
|
Morgan Stanley's ONCS Position: Q2 2023 in Review
Morgan Stanley sold out of OncoSec Medical Incorporated (ONCS) in Q2 2023, closing a stake of 73 shares — an estimated $188 sold.
Morgan Stanley first reported a position in ONCS in Q2 2015 and held it in 32 quarters. The position peaked at $288K in Q2 2015. 0 funds tracked by Wall St. Rank hold ONCS as of Q2 2023.
- Morgan Stanley reported no remaining OncoSec Medical Incorporated position as of Q2 2023 after selling out during the quarter.
- Morgan Stanley sold 73 OncoSec Medical Incorporated shares in Q2 2023, an estimated $188.
- Morgan Stanley first reported a position in OncoSec Medical Incorporated in Q2 2015 and held it in 32 quarters.
- Morgan Stanley's OncoSec Medical Incorporated position peaked at $288K in Q2 2015.
- 0 funds tracked by Wall St. Rank held OncoSec Medical Incorporated as of Q2 2023.
Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.